查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827416

按藥物類型、技術和治療領域分類的藥物研發市場—2025-2032 年全球預測

Drug Discovery Market by Drug Type, Technology, Therapeutic Area - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物研發市場規模將成長至 2,098.7 億美元，複合年成長率為 14.48%。

主要市場統計數據
基準年2024年 711.2億美元
預計2025年 811.1億美元
預測年份：2032年 2098.7億美元
複合年成長率（%） 14.48%

透過摘要技術促進因素、監管壓力和影響創新的策略重點，為下一代治療和藥物發現平台奠定基礎

隨著生物學、工程學和資料科學的融合，藥物研發領域持續加速發展，創造出從假設到先導分子的新途徑。分析自動化、計算化學和多組體學分析的進步正在縮短藥物研發時間，而法律規範和付款人的期望則推動轉化價值的更早展現。在此背景下，從試劑採購到後期轉化驗證，公司必須應對科學機會與營運摩擦之間的複雜相互作用。

事實上，這種環境有利於嚴謹的投資組合管理和跨職能協作。轉化研究團隊、外部創新合作夥伴和生產團隊必須圍繞明確的「可行/不可行」標準和降低風險的里程碑達成一致，以確保投資專注於具有差異化生物學特性和合理開發路徑的候選化合物。此外，平台技術和資料互通性的重要性日益提升，使得數位化準備和分析能力與濕實驗室實力一樣具有戰略意義。當相關人員考慮如何配置資本和人才時，他們應該兼顧短期可行性和長期平台價值，以確保研發工作能帶來永續的競爭優勢。

確定變革性的科學、技術和經營模式轉變，以重塑藥物發現工作流程並加速轉化研究成果

幾項變革性轉變正在重塑藥物研發的營運和策略格局。首先，高內涵資料流與機器學習的整合，使得假設生成和候選藥物篩選達到了前所未有的規模，將重點從偶然發現轉向資料驅動的先導化合物篩選。其次，透過自動化和標準化試劑實現實驗室工作流程的模組化，降低了差異性，並使得跨分散站點的實驗可重複，從而支援全球協作和快速迭代。

第三，生技藥品工程和小分子融合的進步正在拓展可尋址的生物領域，迫使多學科團隊重新思考標靶選擇和模式策略。第四，監管機構和付款方越來越重視開發早期強力的轉化證據，強調預測性臨床前模型和臨床相關的生物標記。最後，從技術許可到共同開發聯盟等策略夥伴關係關係正在蓬勃發展。總而言之，這些轉變要求各機構採用靈活的營運模式，投資可互通的平台，並建立夥伴關係，以加速發現，同時管理技術和商業性風險。

分析2025年美國政策和關稅的累積變化及其對供應鏈、採購和製造策略的連鎖反應

2025年，美國實施的政策變化和關稅調整，為藥物研發實驗室使用的試劑、設備和關鍵零件的採購帶來了新的複雜性。關稅調整影響了進口實驗室用具和某些生化試劑，迫使採購團隊重新評估供應商關係、前置作業時間和總到岸成本。為此，許多組織轉向了強調雙重採購、延長合約期限以及與供應商更緊密合作的籌資策略，以確保優先分配並減少干擾。

在營運方面，進口成本的上升促使一些集團優先考慮國內高價值製造程序，或與當地供應商協商批量合約。同時，研究機構加快了替代試劑的資格確認和跨聯盟試劑共用，以保持實驗的連續性。雖然這些調整需要短期投資和流程重新設計，但也促進了長期供應商的發展和更強大的風險管理實踐。展望未來，發現研究的領導者應繼續關注政策發展，將關稅敏感性納入其採購模式，並維持靈活的採購通訊協定，以因應跨境貿易條件的突然變化。

識別跨藥物類型的細分主導機會區，實行技術和治療領域能夠為優先排序和投資決策提供資訊

從細分市場觀點來看，其對策略、產能投資和夥伴關係設計的影響存在差異。生物製藥和小分子藥物的開發路徑不同，這決定了上游藥物發現的優先順序和下游的生產決策。生物製藥通常需要在表達系統和分析表徵方面進行大量投資，而小分子藥物則更注重藥物化學、ADMET分析和可擴展的合成路線。同時，組合化學和高通量篩檢加速了化學多樣性探索和候選化合物的鑑定。奈米技術和藥物基因體學進一步擴展了標靶給藥和患者分層的套件，從而能夠實現更精準的轉化策略。

治療領域細分也影響科學研究重點和商業性規劃。腫瘤學和神經病學需要複雜的轉化模型和專業的生物標記策略，而感染疾病和免疫性疾病通常需要快速反應和強大的病原體生物學專業知識。循環系統疾病和消化器官系統病需要長期安全性分析和人群分層考慮。這些細分視角將指導公司如何分配藥物研發工作，選擇哪些外部合作夥伴來獲得特定能力，以及如何平衡內部平台和外包服務的投資，以最大限度地提高科學研究產量和營運韌性。

檢驗影響全球資源分配、臨床試驗安排和製造足跡的區域動態和跨境合作模式

區域動態對組織在何處部署能力、進行臨床試驗和採購組件有重大影響。美洲地區擁有強大的創業投資、專業服務供應商和轉化基礎設施，支持先導化合物從發現到臨床的快速轉化。歐洲、中東和非洲擁有深厚的科學專業知識、多樣化的法規環境以及對合作研究網路的高度重視，使其對基於聯盟的計畫和自適應試驗設計具有吸引力。亞太地區擁有高生產能力、蓬勃發展的生物技術生態系統和龐大的臨床研究患者群體，使其成為擴大生產規模和加快患者招募的策略選擇。

由於各地區監管、報銷和營運情況各有不同，公司應制定既能反映本地優勢又能維持全球一致性的區域策略。實現這一目標的方法包括：使臨床開發計畫與各地區的監管路徑保持一致，建立區域卓越中心以提升核心競爭力，並協調跨境資料管治，在滿足司法管轄區合規要求的同時，實現可重複的科學研究。按地區合理分配資產和夥伴關係關係，可以縮短獲得洞察的時間，並提高轉化研究成果從實驗室到臨床轉化的成功率。

介紹主要公司和創新合作夥伴，以揭示藥物發現生態系統中的競爭地位、夥伴關係趨勢和能力差距

重點關注企業和合作聯盟，可以發現能力集中的領域和仍然存在的差距。一些公司透過結合硬體、化學和數據分析的專有平台實現差異化，從而加速迭代發現週期並提供差異化服務模式。另一些公司則透過策略聯盟拓展業務廣度，建構涵蓋外包研究供應商、學術聯盟和合約研究機構的能力組合，從而能夠在不承擔固定成本負擔的情況下獲得專業知識。此外，眾多技術創新者正逐步推動檢測靈敏度、微型化和通量的提升，迫使現有企業重新思考其營運模式和投資重點。

在整個生態系統中，成功的公司透過整合嚴格的檢驗路徑和臨床相關性篩選器，展現出將平台能力轉化為轉化證據的能力。他們也注重在關鍵地區的營運自由，同時務實地管理智慧財產權，並利用合作許可來擴展開發能力。對於評估競爭定位的公司而言，一個關鍵問題是，是投資於專有平台開發，尋求增值合作夥伴關係以填補能力差距，還是採用平衡控制力和靈活性的混合方法。最佳路徑取決於投資組合的雄心、風險接受度以及特定治療領域需要臨床檢驗的速度。

為產業領導者提供實用且具影響力的建議，以簡化其開發平臺、降低供應鏈風險並利用新興平台技術

產業領導者應採取有意識的措施，將科學研究目標與營運能力結合，同時在不確定的環境中保留選擇。首先，透過投資數據標準、模組化自動化和檢驗的分析技術來增強平台互通性，確保不同實驗室和不同設備產生的結果具有可比性和可操作性。其次，制定採購和供應商發展策略，減少對單一來源的依賴，並納入跨境中斷的緊急應變計畫。第三，優先考慮早期轉化驗證，並透過將臨床導向的檢測方法、患者來源的模型和生物標記開發整合到藥物發現工作流程中來限制下游人員流失。

此外，領導者應培養一種組合式的外部化方法：選擇性地將核心差異化要素內包，同時將標準化能力外包給高品質的合作夥伴。為了配合這些營運舉措，應投資於融合濕實驗室專業知識、資料科學和監管敏銳度的人才項目，並制定獎勵以獎勵里程碑主導的進度。最後，應推行務實的合作模式，例如有時限的聯盟和基於里程碑的合資企業，以便在無需長期資本投入的情況下快速獲取相關能力。將這些行動結合起來，將使組織能夠將科學潛力轉化為永續的產品線和富有韌性的業務。

我們描述了我們用來整合主要研究和次要研究的嚴格的混合方法研究途徑，以確保可複製的見解和策略相關性。

這些洞察背後的研究採用了混合方法，結合了初步訪談、技術文獻整合和系統性能力圖譜分析。初步研究包括與藥物研發科學家、採購主管和監管專家進行結構化對話，以了解營運痛點和策略重點。二級資訊來源包括同行評審出版物、監管指南文件和技術檢驗報告，以檢驗技術主張並揭示創新軌跡。數據整合優先考慮可重複性和可追溯性，將具體觀察結果與原始資料和專家歸因聯繫起來。

為確保嚴謹性，能力評估重點在於成熟度、擴充性和轉化相關性，並採用跨技術和跨地區的一致評估框架。敏感度分析考慮了營運風險狀況如何隨著供應鏈風險敞口、監管途徑和夥伴關係模式的變化而變化。透過與領域專家的最後覆核和迭代評審週期，對評估結果進行了檢驗，從而為高階主管和技術領導者提供切實可行的洞察。

創建整合技術、監管和商業性因素的明確觀點，為經營團隊決策和策略藍圖提供訊息

總而言之，當今的發現時代要求組織既要有科學雄心，又要有嚴謹的運作紀律。設備開發、計算建模和轉化生物學領域的突破創造了前所未有的機遇，但它們也面臨著供應鏈脆弱性、不斷變化的政策環境以及對早期臨床試驗日益成長的期望等現實問題。整合互通平台、務實的夥伴關係策略和強大的供應商管理的公司將佔據有利地位，能夠將發現轉化為臨床進展和商業性價值。

從洞察到影響力的轉變，需要對平台整合、跨學科人才和採購慣例進行有針對性的投資，以減少單點故障的風險。透過將科學嚴謹性與策略性營運設計結合，領導者可以加速轉換路徑，保護關鍵工作流程免受干擾，並保持長期創新。這些優先事項應體現在董事會層面的討論、研發規劃週期和跨職能措施中，以確保藥物研發工作保持韌性、專注力，並符合患者和付款人的期望。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 利用人工智慧驅動的分子對接和預測建模工具加速腫瘤學研發管線中的先導藥物最適化
  • 採用基於 CRISPR 的基因編輯平台進行罕見疾病研究中的體內治療候選藥物篩檢
  • 實施雲原生生物資訊學工作流程，簡化藥物標靶發現的多組體學資料整合與分析
  • 整合器官晶片微生理系統以提高臨床前毒性評估的轉換準確性
  • 引進高通量單細胞定序技術，在複雜的腫瘤微環境中尋找新的藥物標靶
  • 利用機器學習演算法對錶型藥物篩檢中的高內涵成像偵測進行即時分析
  • 探索基於生成對抗網路的人工智慧驅動的從頭藥物設計框架，以擴大化學空間的多樣性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：以藥物類型分類的藥物研發市場

  • 生物製藥
  • 小分子藥物

第9章 藥物研發市場（依技術）

  • 生物分析儀器
  • 生物晶片
  • 生物資訊學
  • 組合化學
  • 高通量篩檢
  • 奈米科技
  • 藥物基因組學

第 10 章：按治療領域分類的藥物研發市場

  • 心血管疾病
  • 消化器官系統疾病
  • 感染疾病及免疫系統疾病
  • 神經病學
  • 腫瘤學

第11章 藥物研發市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 藥物研發市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 藥物研發市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Alacrita Holdings Limited
    • Amgen Inc.
    • Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
    • Astrazeneca PLC
    • Atomwise, Inc.
    • BenevolentAI
    • Bio-Rad Laboratories, Inc.
    • Merck & Co., Inc.
Product Code: MRR-434CCDA0516F

The Drug Discovery Market is projected to grow by USD 209.87 billion at a CAGR of 14.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 71.12 billion
Estimated Year [2025] USD 81.11 billion
Forecast Year [2032] USD 209.87 billion
CAGR (%) 14.48%

Setting the stage for next-generation therapeutics and discovery platforms by summarizing technological drivers, regulatory pressures, and strategic priorities shaping innovation

The drug discovery landscape continues to evolve at an accelerated pace as biology, engineering, and data science converge to create new pathways from hypothesis to lead molecule. Advances in assay automation, computational chemistry, and multiomic analytics are compressing discovery timelines while regulatory frameworks and payer expectations are encouraging earlier demonstration of translational value. Against this backdrop, organizations must navigate a complex interplay of scientific opportunity and operational friction that ranges from reagent sourcing to late-stage translational validation.

In practical terms, this environment rewards disciplined portfolio management and cross-functional collaboration. Translational research groups, external innovation partners, and manufacturing teams must align around clear go/no-go criteria and de-risking milestones so that investment is concentrated on candidates with differentiated biology and plausible development pathways. Moreover, the growing importance of platform technologies and data interoperability means that digital readiness and analytic capability are as strategic as wet-lab prowess. As stakeholders evaluate where to deploy capital and talent, they should consider both near-term feasibility and longer-term platform value so that discovery efforts deliver sustainable competitive advantage.

Identifying the transformative scientific, technological, and business model shifts that are rewriting drug discovery workflows and accelerating translational research outcomes

Several transformative shifts are rewriting the operational and strategic contours of drug discovery. First, the integration of high-content data streams with machine learning is enabling hypothesis generation and candidate triage at scales that were previously impractical, shifting emphasis from serendipitous findings toward data-driven lead selection. Second, modularization of laboratory workflows through automation and standardized reagents reduces variability and enables reproducible experiments across distributed sites, which in turn supports global collaboration and faster iteration.

Third, advances in biologics engineering and small molecule convergence are expanding the addressable biological space, prompting cross-disciplinary teams to rethink target selection and modality strategy. Fourth, regulatory and payer expectations increasingly reward robust translational evidence earlier in development, which places a premium on predictive preclinical models and clinically relevant biomarkers. Finally, strategic partnerships-ranging from technology licensing to co-development alliances-are proliferating as organizations seek to combine complementary capabilities rather than build everything in-house. Together, these shifts demand that organizations adopt flexible operating models, invest in interoperable platforms, and cultivate partnerships that accelerate discovery while managing technical and commercial risk.

Analyzing the cumulative policy and tariff changes in the United States during 2025 and their ripple effects across supply chains, sourcing, and manufacturing strategies

Policy changes and tariff adjustments implemented in the United States during 2025 introduced new layers of complexity for sourcing reagents, instruments, and critical components used across discovery laboratories. Tariff adjustments affected imported laboratory equipment and certain biochemical reagents, prompting procurement teams to reassess supplier relationships, lead times, and total landed costs. In response, many organizations have shifted procurement strategies to emphasize dual sourcing, longer contract horizons, and closer collaboration with suppliers to secure priority allocations and mitigate disruption.

Operationally, elevated import costs led some groups to prioritize onshoring for high-value manufacturing steps or to negotiate volume-based agreements with regional suppliers. Concurrently, research organizations accelerated qualification of alternative reagents and reagents sharing across consortia to preserve experimental continuity. While these adjustments required near-term investment and process redesign, they also catalyzed longer-term supplier development and more robust risk management practices. Moving forward, discovery leaders should continue to monitor policy developments, embed tariff sensitivity into sourcing models, and maintain agile procurement protocols that can respond to sudden changes in cross-border trade conditions.

Uncovering segmentation-driven opportunity zones across drug types, enabling technologies, and therapeutic areas to inform prioritization and investment decisions

Segment-level perspective reveals differentiated implications for strategy, capability investment, and partnership design. When considering drug types, the distinct development pathways for Biologic Drugs versus Small Molecule Drugs shape upstream discovery priorities and downstream manufacturing decisions; biologics typically require deeper investment in expression systems and analytical characterization, while small molecules often emphasize medicinal chemistry, ADMET profiling, and scalable synthetic routes. In terms of enabling technologies, organizations can unlock value by targeting platform integration across Bioanalytical Instruments, Biochips, and Bioinformatics to enable high-resolution data capture and decision automation, while Combinatorial Chemistry and High Throughput Screening accelerate chemical diversity exploration and candidate identification. Nanotechnology and Pharmacogenomics further expand the toolkit for targeted delivery and patient stratification, enabling more precise translational strategies.

Therapeutic area segmentation also directs scientific focus and commercial planning. Oncology and Neurology demand complex translational models and specialized biomarker strategies, whereas Infectious & Immune system Diseases often require rapid-response capabilities and robust pathogen biology expertise. Cardiovascular Disease and Digestive System Diseases call for long-term safety profiling and population stratification considerations. These segmentation lenses together inform where firms should allocate discovery effort, which external partners to engage for specific capabilities, and how to stage investments in in-house platforms versus outsourced services to maximize scientific yield and operational resilience.

Examining regional dynamics and cross-border collaboration patterns that influence resource allocation, clinical trial placement, and manufacturing footprints worldwide

Regional dynamics materially influence where organizations locate capabilities, run trials, and source components. In the Americas, there is strong concentration of venture capital, specialist service providers, and translational infrastructure that supports rapid progression from lead discovery to clinic; this concentration encourages close proximity between discovery teams and clinical collaborators. Europe, Middle East & Africa combines deep scientific expertise, diverse regulatory environments, and an emphasis on collaborative research networks, making it attractive for consortium-based programs and adaptive trial designs. Asia-Pacific presents a mix of high-capacity manufacturing, rapidly growing biotech ecosystems, and a large patient population for clinical research, which makes it a strategic choice for scaling manufacturing and accelerating patient recruitment.

Because regulatory, reimbursement, and operational realities differ across these regions, organizations should design regional strategies that reflect local advantages while maintaining global coherence. This can be achieved by aligning clinical development plans to local regulatory pathways, establishing regional centers of excellence for core capabilities, and orchestrating cross-border data governance that enables reproducible science while meeting jurisdictional compliance requirements. Thoughtful regional allocation of assets and partnerships reduces time-to-insight and enhances the probability that translational findings will survive the transition from lab to clinic.

Profiling leading corporate actors and innovation collaborators to reveal competitive positioning, partnership trends, and capability gaps in discovery ecosystems

A focused view of corporate players and collaborative consortia highlights where capabilities concentrate and where gaps remain. Some organizations distinguish themselves through proprietary platforms that combine hardware, chemistry, and data analytics, enabling them to accelerate iterative discovery cycles and offer differentiated service models. Others pursue breadth through strategic alliances, building capability portfolios that include outsourced research providers, academic partnerships, and contract development organizations to access specialized expertise without bearing full fixed-cost burdens. In addition, a cohort of technology innovators is driving step-change improvements in assay sensitivity, miniaturization, and throughput, which forces incumbents to rethink operational models and investment priorities.

Across the ecosystem, successful actors demonstrate an ability to translate platform capability into translational evidence by integrating rigorous validation pathways and clinical relevance filters. They also manage intellectual property pragmatically, focusing on freedom-to-operate in key geographies while leveraging collaborative licensing to expand development capacity. For organizations assessing competitive positioning, the critical questions are whether to invest in unique platform development, pursue accretive partnerships to fill capability gaps, or adopt a hybrid approach that balances control and flexibility. The optimal path depends on portfolio ambitions, risk tolerance, and the pace at which a given therapeutic area requires clinical validation.

Delivering pragmatic, high-impact recommendations for industry leaders to align R&D pipelines, de-risk supply chains, and capitalize on emergent platform technologies

Industry leaders should take deliberate steps to align scientific ambition with operational capability while preserving optionality in an uncertain environment. First, strengthen platform interoperability by investing in data standards, modular automation, and validated analytics so that results generated in different labs or with different instruments remain comparable and actionable. Second, establish procurement and supplier development strategies that reduce single-source dependencies and incorporate contingency planning for cross-border disruptions. Third, prioritize translational validation early by integrating clinically oriented assays, patient-derived models, and biomarker development into discovery workflows to reduce downstream attrition.

In addition, leaders should cultivate a portfolio approach to externalization: selectively insource core differentiators while outsourcing standardized capabilities to high-quality partners. Complementing these operational moves, invest in talent programs that blend wet-lab expertise, data science, and regulatory insight, and align incentives to reward milestone-driven progress. Finally, pursue pragmatic collaboration models-such as time-limited consortia or milestone-based joint ventures-that enable rapid access to capability without long-term capital overhang. Taken together, these actions will help organizations convert scientific promise into sustainable pipelines and resilient operations.

Explaining the rigorous mixed-method research approach used to synthesize primary and secondary intelligence, ensuring reproducible insights and strategic relevance

The research underpinning these insights employed a mixed-methods approach that combined primary interviews, technical literature synthesis, and systematic capability mapping. Primary engagements included structured conversations with discovery scientists, procurement leaders, and regulatory experts to capture operational pain points and strategic priorities. Secondary sources encompassed peer-reviewed publications, regulatory guidance documents, and technology validation reports to verify technical claims and contextualize innovation trajectories. Data synthesis prioritized reproducibility and traceability, linking specific observations to source material and expert attribution.

To ensure rigor, capability assessments applied consistent evaluation frameworks across technologies and geographies, focusing on maturity, scalability, and translational relevance. Sensitivity analyses explored how variations in supply chain exposure, regulatory pathways, and partnership models could alter operational risk profiles. Throughout, findings were validated through cross-checks with domain experts and iterative review cycles, producing a set of insights designed to be actionable for executives and technical leaders alike.

Drawing conclusive perspectives that integrate technological, regulatory, and commercial factors to inform executive decision-making and strategic roadmaps

In conclusion, the current era of discovery demands that organizations be both scientifically ambitious and operationally disciplined. Breakthroughs in instrumentation, computational modeling, and translational biology create unprecedented opportunity, yet they operate within a reality of supply chain fragility, evolving policy landscapes, and heightened expectations for early clinical relevance. Those who integrate interoperable platforms, pragmatic partnership strategies, and robust supplier management will be better positioned to translate discovery into clinical progress and commercial value.

Moving from insight to impact requires targeted investments in platform integration, talent that spans disciplines, and procurement practices that reduce exposure to single points of failure. By marrying scientific rigor with strategic operational design, leaders can accelerate translational pathways, protect critical workflows from disruption, and sustain long-term innovation. These priorities should inform board-level discussions, R&D planning cycles, and cross-functional initiatives to ensure that discovery efforts remain resilient, focused, and aligned with patient and payer expectations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Utilization of AI-driven molecular docking and predictive modeling tools to accelerate lead optimization in oncology pipelines
  • 5.2. Adoption of CRISPR-based gene editing platforms for in vivo therapeutic candidate screening in rare disease research
  • 5.3. Implementation of cloud-native bioinformatics workflows to streamline multi-omics data integration and analysis for drug target discovery
  • 5.4. Integration of organ-on-chip microphysiological systems to improve translational accuracy of preclinical toxicity assessments
  • 5.5. Deployment of high-throughput single-cell sequencing technologies to identify novel drug targets in complex tumor microenvironments
  • 5.6. Leveraging machine learning algorithms for real-time analysis of high-content imaging assays in phenotypic drug screening
  • 5.7. Exploration of AI-driven de novo drug design frameworks using generative adversarial networks to expand chemical space diversity

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Market, by Drug Type

  • 8.1. Biologic Drugs
  • 8.2. Small Molecule Drugs

9. Drug Discovery Market, by Technology

  • 9.1. Bioanalytical Instruments
  • 9.2. Biochips
  • 9.3. Bioinformatics
  • 9.4. Combinatorial Chemistry
  • 9.5. High Throughput Screening
  • 9.6. Nanotechnology
  • 9.7. Pharmacogenomics

10. Drug Discovery Market, by Therapeutic Area

  • 10.1. Cardiovascular Disease
  • 10.2. Digestive System Diseases
  • 10.3. Infectious & Immune system Diseases
  • 10.4. Neurology
  • 10.5. Oncology

11. Drug Discovery Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Drug Discovery Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Drug Discovery Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Abbott Laboratories
    • 14.3.2. Agilent Technologies, Inc.
    • 14.3.3. Alacrita Holdings Limited
    • 14.3.4. Amgen Inc.
    • 14.3.5. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
    • 14.3.6. Astrazeneca PLC
    • 14.3.7. Atomwise, Inc.
    • 14.3.8. BenevolentAI
    • 14.3.9. Bio-Rad Laboratories, Inc.
    • 14.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 144. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 145. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 152. AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. ASEAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. ASEAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. ASEAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. ASEAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. ASEAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 170. ASEAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 171. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GCC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GCC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GCC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. GCC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. GCC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 178. GCC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. BRICS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. BRICS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. BRICS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 194. BRICS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 195. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. G7 DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. G7 DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. G7 DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. G7 DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. G7 DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 202. G7 DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 203. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. NATO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. NATO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. NATO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. NATO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. NATO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 210. NATO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 219. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 225. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 231. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 243. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 249. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 254. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 255. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 260. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 261. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 266. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 267. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 272. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 273. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 278. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 279. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 284. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 285. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 290. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 291. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 296. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 297. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 302. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 303. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 304. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024